Denali Therapeutics (NASDAQ:DNLI) used an analyst call from the 2026 WORLD Symposium in San Diego to highlight new and ...
Analysis from continued follow-up of Phase 1/2 clinical trial data in Hunter syndrome (MPS II) reinforces potential for tividenofusp alfa ...
Denali Therapeutics announced it will present past and ongoing clinical and preclinical data from its Enzyme TransportVehicle (ETV) programs at the 22nd Annual WORLDSymposium in San Diego, ...